CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 75 of 219 entries

View as:

Bioequivalence Study to Compare Two Formulations of Deanxit®

Phase: N/A Priority: Normal

NCT ID: NCT03472651 Org: User:

Start: 05/07/18 End: 06/28/18 Due: 06/28/19

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Phase: N/A Priority: Normal

NCT ID: NCT05304910 Org: User:

Start: 03/18/22 End: 10/30/22 Due: 10/30/23

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02231450 Org: User:

Start: 07/31/14 End: - Due: -

A Study Investigating Lu AG06474 in Healthy Young Participants

Phase: N/A Priority: Normal

NCT ID: NCT05943327 Org: User:

Start: 06/28/23 End: 07/19/24 Due: 07/19/25

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Phase: N/A Priority: Normal

NCT ID: NCT01837797 Org: User:

Start: 04/30/13 End: 05/31/14 Due: 05/31/15

Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women

Phase: N/A Priority: Normal

NCT ID: NCT01652313 Org: User:

Start: 05/31/12 End: - Due: -

A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease

Phase: N/A Priority: Normal

NCT ID: NCT00862940 Org: User:

Start: 09/30/05 End: 04/30/09 Due: 04/30/10

Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

Phase: N/A Priority: Normal

NCT ID: NCT02340195 Org: User:

Start: 01/31/15 End: - Due: -

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Phase: N/A Priority: Normal

NCT ID: NCT02871297 Org: User:

Start: 08/17/16 End: 04/19/22 Due: 04/19/23

Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Phase: N/A Priority: Normal

NCT ID: NCT00839423 Org: User:

Start: 08/31/06 End: 09/30/07 Due: 09/30/08

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02019394 Org: User:

Start: 12/31/13 End: - Due: -

Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

Phase: N/A Priority: Normal

NCT ID: NCT02195817 Org: User:

Start: 08/31/14 End: 02/29/16 Due: 02/28/17

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Phase: N/A Priority: Normal

NCT ID: NCT03611569 Org: User:

Start: 07/25/18 End: 07/26/21 Due: 07/26/22

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Phase: N/A Priority: Normal

NCT ID: NCT05669950 Org: User:

Start: 12/19/22 End: 02/01/28 Due: 02/01/29

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Phase: N/A Priority: Normal

NCT ID: NCT04965675 Org: User:

Start: 06/30/21 End: 03/31/26 Due: 03/31/27

Observational Study in Multiple System Atrophy

Phase: N/A Priority: Normal

NCT ID: NCT05453058 Org: User:

Start: 06/25/22 End: 03/12/24 Due: 03/12/25

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Phase: N/A Priority: Normal

NCT ID: NCT05177029 Org: User:

Start: 11/26/21 End: 12/29/21 Due: 12/29/22

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

Phase: N/A Priority: Normal

NCT ID: NCT06471829 Org: User:

Start: 06/19/24 End: 03/15/28 Due: 03/15/29

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT03793712 Org: User:

Start: 12/27/18 End: 09/03/20 Due: 09/03/21

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT01795547 Org: User:

Start: 02/28/13 End: 09/30/14 Due: 09/30/15

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT00654706 Org: User:

Start: 03/31/08 End: 03/31/10 Due: 03/31/11

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Phase: N/A Priority: Normal

NCT ID: NCT05164172 Org: User:

Start: 12/01/21 End: 03/01/26 Due: 03/01/27

Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease

Phase: N/A Priority: Normal

NCT ID: NCT00857233 Org: User:

Start: 06/30/04 End: 10/31/10 Due: 10/31/11

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Phase: N/A Priority: Normal

NCT ID: NCT03108625 Org: User:

Start: 03/01/17 End: 04/16/20 Due: 04/16/21

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Phase: N/A Priority: Normal

NCT ID: NCT02174094 Org: User:

Start: 03/31/15 End: 08/31/15 Due: 08/31/16

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Bioequivalence Study to Compare Two Formulations of Deanxit®	NCT03472651	H. Lundbeck A/S	user2@example.com	None	2018-05-07	2018-06-28	2019-06-28	-	-	2025-07-14
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants	NCT05304910	H. Lundbeck A/S	user2@example.com	None	2022-03-18	2022-10-30	2023-10-30	-	-	2025-07-14
Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects	NCT02231450	H. Lundbeck A/S	user2@example.com	None	2014-07-31	-	-	-	-	2025-07-14
A Study Investigating Lu AG06474 in Healthy Young Participants	NCT05943327	H. Lundbeck A/S	user2@example.com	None	2023-06-28	2024-07-19	2025-07-19	-	-	2025-07-14
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment	NCT01837797	H. Lundbeck A/S	user2@example.com	None	2013-04-30	2014-05-31	2015-05-31	-	-	2025-07-14
Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women	NCT01652313	H. Lundbeck A/S	user2@example.com	None	2012-05-31	-	-	-	-	2025-07-14
A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease	NCT00862940	H. Lundbeck A/S	user2@example.com	None	2005-09-30	2009-04-30	2010-04-30	-	-	2025-07-14
Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function	NCT02340195	H. Lundbeck A/S	user2@example.com	None	2015-01-31	-	-	-	-	2025-07-14
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age	NCT02871297	H. Lundbeck A/S	user2@example.com	None	2016-08-17	2022-04-19	2023-04-19	-	-	2025-07-14
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults	NCT00839423	H. Lundbeck A/S	user2@example.com	None	2006-08-31	2007-09-30	2008-09-30	-	-	2025-07-14
Absolute Bioavailability of Lu AE58054 in Healthy Subjects	NCT02019394	H. Lundbeck A/S	user2@example.com	None	2013-12-31	-	-	-	-	2025-07-14
Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care	NCT02195817	H. Lundbeck A/S	user2@example.com	None	2014-08-31	2016-02-29	2017-02-28	-	-	2025-07-14
Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease	NCT03611569	H. Lundbeck A/S	user2@example.com	None	2018-07-25	2021-07-26	2022-07-26	-	-	2025-07-14
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia	NCT05669950	H. Lundbeck A/S	user2@example.com	None	2022-12-19	2028-02-01	2029-02-01	-	-	2025-07-14
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine	NCT04965675	H. Lundbeck A/S	user2@example.com	None	2021-06-30	2026-03-31	2027-03-31	-	-	2025-07-14
Observational Study in Multiple System Atrophy	NCT05453058	H. Lundbeck A/S	user2@example.com	None	2022-06-25	2024-03-12	2025-03-12	-	-	2025-07-14
Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants	NCT05177029	H. Lundbeck A/S	user2@example.com	None	2021-11-26	2021-12-29	2022-12-29	-	-	2025-07-14
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease	NCT06471829	H. Lundbeck A/S	user2@example.com	None	2024-06-19	2028-03-15	2029-03-15	-	-	2025-07-14
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia	NCT03793712	H. Lundbeck A/S	user2@example.com	None	2018-12-27	2020-09-03	2021-09-03	-	-	2025-07-14
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia	NCT01795547	H. Lundbeck A/S	user2@example.com	None	2013-02-28	2014-09-30	2015-09-30	-	-	2025-07-14
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia	NCT00654706	H. Lundbeck A/S	user2@example.com	None	2008-03-31	2010-03-31	2011-03-31	-	-	2025-07-14
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine	NCT05164172	H. Lundbeck A/S	user2@example.com	None	2021-12-01	2026-03-01	2027-03-01	-	-	2025-07-14
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease	NCT00857233	H. Lundbeck A/S	user2@example.com	None	2004-06-30	2010-10-31	2011-10-31	-	-	2025-07-14
Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age	NCT03108625	H. Lundbeck A/S	user2@example.com	None	2017-03-01	2020-04-16	2021-04-16	-	-	2025-07-14
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome	NCT02174094	H. Lundbeck A/S	user2@example.com	None	2015-03-31	2015-08-31	2016-08-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance